CRNX
$37.89
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidat...
Recent News
Is Crinetics Pharmaceuticals (CRNX) Pricing Reflect Its Sharp Swings And DCF Upside Potential
If you are trying to figure out whether Crinetics Pharmaceuticals at around US$37.49 is still good value or looking stretched, you are in the right place. The stock has seen mixed returns, with a 1.9% decline over the last week and a 21.3% decline over the past month, while still showing a 117.3% return over three years and 127.3% over five years. Those swings have kept Crinetics on many investors' watchlists, and recent company developments have continued to shape how the market prices its...
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know
This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets.
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology.
Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf.
Executives from Crinetics Pharmaceuticals (NASDAQ:CRNX) used an investor discussion at TD Cowen’s 46th Annual Healthcare Conference to highlight early U.S. commercial progress for its newly launched acromegaly drug, outline upcoming regulatory and clinical milestones, and describe how its pipeline i